Rapid ASPECTS receives clearance as first neuroimaging analysis device in computer-aided diagnostic category.
Advanced stroke imaging company RapidAI announced today it has secured 510(k) clearance from the U.S. Food & Drug Administration for its neuroimaging analysis device Rapid ASPECTS.
This is the first device to receive clearance in the computer-aided diagnostic software (CADx) category, and, according to a company statement, it is the only product confirmed to improve physician interpretations of non-contract CT using a standardized APSECT score. It can be particularly useful for less experienced readers, company officials said.
“The FDA’s advanced CADx clearance has never been granted to a neuroimaging solution before,” said Jim Rosa, senior vice president of regulatory and clinical at RapidAI. “Through a combination of clinically validated advances in AI and machine learning, Rapid ASPECTS offers a glimpse into the future of stroke imaging.”
Related Content: CT Predicts Stroke Patients Benefitting From Endovascular Thrombectomy
Rapid ASPECTS is based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, and it uses a validated machine-learning algorithm to identify affected regions of the brain and create an ASPECT score than can pinpoint early signs of stroke in non-contrast CT scans. In doing so, it can help providers identify areas of the brain that have irreversible injury.
Overall, according to company information, Rapid ASPECTS offers three main features:
Ultimately, company officials said, Rapid ASPECTS is designed to facilitate better patient outcomes.
“Rapid ASPECTS represents the next AI-powered step forward in stroke imaging, and the groundbreaking CADx clearance from the FDA puts it in a class by itself,” said RapidAI co-founder Greg Albers, M.D., professor of neurology at Stanford University and director of the Stanford Stroke Center. “In addition to helping stroke teams with faster triage and transfer decision, Rapid ASPECTS also improves the accuracy of typical readers.”
Rapid ASPECTS is already available internationally and will be commercially available in the United States later in July.
What a New Meta-Analysis Reveals About Fractional Flow Reserve Assessment with Computed Tomography
May 13th 2024While acknowledging variable accuracy overall with CT-derived fractional flow reserve (FFR-CT) values, researchers found that the accuracy rate increased to 90 percent for FFR-CT values greater > 0.90 and < 0.49.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.